These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23242124)

  • 21. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment.
    Forlenza OV; Diniz BS; Talib LL; Mendonça VA; Ojopi EB; Gattaz WF; Teixeira AL
    Dement Geriatr Cogn Disord; 2009; 28(6):507-12. PubMed ID: 19996595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased plasma levels of lipocalin 2 in mild cognitive impairment.
    Choi J; Lee HW; Suk K
    J Neurol Sci; 2011 Jun; 305(1-2):28-33. PubMed ID: 21463871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease.
    Marksteiner J; Kemmler G; Weiss EM; Knaus G; Ullrich C; Mechtcheriakov S; Oberbauer H; Auffinger S; Hinterhölzl J; Hinterhuber H; Humpel C
    Neurobiol Aging; 2011 Mar; 32(3):539-40. PubMed ID: 19395124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics.
    Villarreal AE; O'Bryant SE; Edwards M; Grajales S; Britton GB;
    Neurodegener Dis Manag; 2016 Jun; 6(3):203-13. PubMed ID: 27229914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between serum haptoglobin and the pathogenesis of Alzheimer's disease.
    Song IU; Kim YD; Chung SW; Cho HJ
    Intern Med; 2015; 54(5):453-7. PubMed ID: 25758069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration.
    Corsi MM; Licastro F; Porcellini E; Dogliotti G; Galliera E; Lamont JL; Innocenzi PJ; Fitzgerald SP
    Biogerontology; 2011 Oct; 12(5):451-4. PubMed ID: 21484243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RAPID progression: tool for screening aggressive course of disease (ACD) in Alzheimer dementia.
    Thavichachart N; Worakul P; Farlow MR
    J Med Assoc Thai; 2011 Apr; 94(4):485-9. PubMed ID: 21591535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation of microRNA-103 and microRNA-107 as potential blood-based biomarkers for disease risk and progression of Alzheimer's disease.
    Wang J; Chen C; Zhang Y
    J Clin Lab Anal; 2020 Jan; 34(1):e23006. PubMed ID: 31420923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.
    Kessler H; Pajonk FG; Bach D; Schneider-Axmann T; Falkai P; Herrmann W; Multhaup G; Wiltfang J; Schäfer S; Wirths O; Bayer TA
    J Neural Transm (Vienna); 2008 Dec; 115(12):1651-9. PubMed ID: 18972062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease.
    Mielke MM; Haughey NJ; Bandaru VV; Weinberg DD; Darby E; Zaidi N; Pavlik V; Doody RS; Lyketsos CG
    J Alzheimers Dis; 2011; 27(2):259-69. PubMed ID: 21841258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease.
    Squitti R; Bressi F; Pasqualetti P; Bonomini C; Ghidoni R; Binetti G; Cassetta E; Moffa F; Ventriglia M; Vernieri F; Rossini PM
    Neurology; 2009 Jan; 72(1):50-5. PubMed ID: 19122030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.
    Porcellini E; Davis EJ; Chiappelli M; Ianni E; Di Stefano G; Forti P; Ravaglia G; Licastro F
    Curr Pharm Des; 2008; 14(26):2659-64. PubMed ID: 18991685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evaluation of thiol-disulfıte balance, ischemıa albumın modıfıcation and seruloplazmine as a new oxidatıve stress in mild cognitive impairment and early stage alzheimer's disease patients.
    Gündüztepe Y; Bukan N; Zorlu E; Karaman Y; Andaç Topkan T; Gurbuz N; Neşelioğlu S; Erel Ö
    J Clin Neurosci; 2020 May; 75():188-194. PubMed ID: 32223973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation between mild cognitive impairment, Alzheimer's disease and depression by means of cued recall.
    Dierckx E; Engelborghs S; De Raedt R; De Deyn PP; Ponjaert-Kristoffersen I
    Psychol Med; 2007 May; 37(5):747-55. PubMed ID: 17164030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma cytokine IL-6 levels and subjective cognitive decline: preliminary findings.
    Keegan AP; Paris D; Luis CA; Abdullah L; Ait-Ghezala G; Beaulieu-Abdelahad D; Pryor M; Chaykin J; Crynen G; Crawford F; Mullan M
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):358-363. PubMed ID: 28639714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation study of the Alzheimer's Disease Assessment Scale-Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities.
    Yang H; Cheng Z; Li Z; Jiang Y; Zhao J; Wu Y; Gu S; Xu H
    Int J Geriatr Psychiatry; 2019 Nov; 34(11):1658-1666. PubMed ID: 31347192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease.
    Bawa KK; Krance SH; Herrmann N; Cogo-Moreira H; Ouk M; Yu D; Wu CY; Black SE; Lanctôt KL; Swardfager W;
    J Neuroinflammation; 2020 Mar; 17(1):84. PubMed ID: 32171317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.